DANIA BEACH, Fla., Oct. 4, 2018 /PRNewswire/ — OrthoSensor, Inc., a leader in sensor-assisted technology for total knee replacement (TKR), today announced the milestone achievement of 50,000 VERASENSE sensors distributed worldwide.
VERASENSE provides surgeons with real-time data during surgery that may help patients return to normal activities faster, improve activity level and experience better knee function.1-3 VERASENSE is transforming primary and revision total knee replacement for surgeons and patients across the globe.
“This milestone for OrthoSensor’s leading product—VERASENSE — is an exciting achievement,” said Steve Seger, Sr. Vice President of Sales and Marketing. “We also have excellent growth opportunities with the recent approvals of VERASENSE in Japan and the FDA clearance of VERASENSE for Zimmer Biomet Persona; we’re just getting started. Furthermore, our partnerships with leading joint replacement companies such as Smith & Nephew, Stryker and Zimmer Biomet allow surgeons around the world to easily adopt VERASENSE in primary and revision total knee procedures–taking out the guess work on soft tissue balance and enhancing implant systems they already use.”
OrthoSensor has built strong evidence for positive clinical outcomes with VERASENSE through 40 peer-reviewed manuscripts, 100+ scientific presentations and more than 15 ongoing clinical studies – 4 of which are level one, randomized controlled trials. The most recent publication reports on excellent 3-year patient-reported satisfaction following VERASENSE use during surgery. To learn more visit orthosensor.com
About OrthoSensor, Inc.
OrthoSensor, Inc., a leader in Sensor-Assisted Total Knee Arthroplasty, develops and commercializes intelligent orthopedic devices and data services that provide quantitative feedback to surgeons and hospitals. The sensor utilizes advanced proprietary sensor and communications technologies, coupled with the company’s innovative software products, to facilitate evidence-based decisions in orthopaedic surgery – with the goal of improving patient outcomes and potentially reducing the cost of treating musculoskeletal disease.
OrthoSensor® VERASENSE™, and OrthoLogIQ® are trademarks of OrthoSensor, Inc.
References:
1. Gustke KA, Golladay GJ, Roche MW, Elson LC, Anderson CR. Primary TKA Patients with Quantifiably Balanced Soft-Tissue Achieve Significant Clinical Gains Sooner than Unbalanced Patients. Advances in Orthopedics, vol. 2014, Article ID 628695, 6 pages, 2014.
2. Gustke KA, Golladay GJ, Roche MW, Elson LC, Anderson CR. A new method for defining balance: promising short-term clinical outcomes of sensor-guided TKA. J Arthroplasty 2014; 29:955–960.
3. 2-Year Clinical Outcomes. OrthoSensor Multicenter Evaluation. Pending publication. Data on file at OrthoSensor, Inc.
4. Gustke, K., Golladay, G., Roche, M., Elson, L., Jerry, G., Anderson, C. The satisfied total knee replacement patient: 3-year multicenter study. EC Orthopedics 9.3 (2018): 122-127.
Contact:
Yvette Cuello
954-666-0282
ycuello@orthosensor.com
SOURCE OrthoSensor, Inc.